Physician profile
David Blaine
NPI 1912968744
$3,277.49
in general payments reported to CMS, 2019-2025
21 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $156 · 2021: $114 · 2022: $1,297 · 2023: $497 · 2024: $459 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,066.92 | 2022 | |
| Glaxosmithkline, LLC. | $513.70 | 2021-2025 | Nucala |
| Inspire Medical Systems, INC. | $364.51 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $249.16 | 2023-2025 | Dupixent |
| Optinose US, INC. | $168.06 | 2019-2025 | |
| Ethicon US, LLC | $165.27 | 2020-2024 | Vistaseal, Prolene |
| Aerin Medical INC. | $118.35 | 2019-2025 | |
| Genzyme Corporation | $91.07 | 2025 | |
| Allergan, INC. | $76.78 | 2019-2022 | |
| Stryker Corporation | $76.27 | 2019-2021 | |
| Ambu INC. | $72.47 | 2021-2024 | |
| Celgene Corporation | $64.14 | 2019 | |
| Organogenesis INC. | $62.38 | 2023 | Puraply |
| Takeda Pharmaceuticals U.S.A., INC. | $42.43 | 2025 | Elaprase |
| Galderma Laboratories, L.P. | $31.08 | 2025 | Nemluvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $30.76 | 2019 | |
| Smith+Nephew, INC. | $21.13 | 2023 | Coblation |
| Abbvie INC. | $19.16 | 2023 | |
| Merck Sharp & Dohme LLC | $17.98 | 2023 | |
| Tactile Systems Technology INC | $13.81 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Blaine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.